- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07795164
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (PERFORMA)
A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Shaheen Tomah, MD
- Telefonnummer: 240-235-0145
- E-mail: performa@altimmune.com
Studiesteder
-
-
Alabama
-
Dothan, Alabama, Forenede Stater, 36301
- Rekruttering
- Altimmune Clinical Study Site
-
-
Arizona
-
Chandler, Arizona, Forenede Stater, 85224
- Rekruttering
- Altimmune Clinical Study Site
-
Tucson, Arizona, Forenede Stater, 85712
- Rekruttering
- Altimmune Clinical Study Site
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- Rekruttering
- Altimmune Clinical Study Site
-
North Little Rock, Arkansas, Forenede Stater, 72117
- Rekruttering
- Altimmune Clinical Study Site
-
-
California
-
Fountain Valley, California, Forenede Stater, 92708
- Rekruttering
- Altimmune Clinical Study Site
-
Fresno, California, Forenede Stater, 93720
- Rekruttering
- Altimmune Clinical Study Site
-
Gardena, California, Forenede Stater, 90247
- Rekruttering
- Altimmune Clinical Study Site
-
Huntington Park, California, Forenede Stater, 90255
- Rekruttering
- Altimmune Clinical Study Site
-
La Mesa, California, Forenede Stater, 91942
- Rekruttering
- Altimmune Clinical Study Site
-
Long Beach, California, Forenede Stater, 90815
- Rekruttering
- Altimmune Clinical Study Site
-
Orange, California, Forenede Stater, 92866
- Rekruttering
- Altimmune Clinical Study Site
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- Altimmune Clinical Study Site
-
Poway, California, Forenede Stater, 92064
- Rekruttering
- Altimmune Clinical Study Site
-
Van Nuys, California, Forenede Stater, 91405
- Rekruttering
- Altimmune Clinical Study Site
-
-
Colorado
-
Englewood, Colorado, Forenede Stater, 80113
- Rekruttering
- Altimmune Clinical Study Site
-
-
Florida
-
Boca Raton, Florida, Forenede Stater, 33434
- Rekruttering
- Altimmune Clinical Study Site
-
Bradenton, Florida, Forenede Stater, 34209
- Rekruttering
- Altimmune Clinical Study Site
-
Miami, Florida, Forenede Stater, 33173
- Rekruttering
- Altimmune Clinical Study Site
-
Miami, Florida, Forenede Stater, 33122
- Rekruttering
- Altimmune Clinical Study Site
-
Miami Lakes, Florida, Forenede Stater, 33016
- Rekruttering
- Altimmune Clinical Study Site
-
Ocala, Florida, Forenede Stater, 34471
- Rekruttering
- Altimmune Clinical Study Site
-
Orlando, Florida, Forenede Stater, 32803
- Rekruttering
- Altimmune Clinical Study Site
-
Port Orange, Florida, Forenede Stater, 32127
- Rekruttering
- Altimmune Clinical Study Site
-
-
Georgia
-
Dalton, Georgia, Forenede Stater, 30720
- Rekruttering
- Altimmune Clinical Study Site
-
-
Indiana
-
South Bend, Indiana, Forenede Stater, 46635
- Rekruttering
- Altimmune Clinical Study Site
-
-
Louisiana
-
Bastrop, Louisiana, Forenede Stater, 71220
- Rekruttering
- Altimmune Clinical Study Site
-
Marrero, Louisiana, Forenede Stater, 70072
- Rekruttering
- Altimmune Clinical Study Site
-
Monroe, Louisiana, Forenede Stater, 71201
- Rekruttering
- Altimmune Clinical Study Site
-
-
Maryland
-
Laurel, Maryland, Forenede Stater, 20708
- Rekruttering
- Altimmune Clinical Study Site
-
-
Massachusetts
-
New Bedford, Massachusetts, Forenede Stater, 02740
- Rekruttering
- Altimmune Clinical Study Site
-
-
Missouri
-
Columbia, Missouri, Forenede Stater, 65201
- Rekruttering
- Altimmune Clinical Study Site
-
Kansas City, Missouri, Forenede Stater, 64131
- Rekruttering
- Altimmune Clinical Study Site
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87107
- Rekruttering
- Altimmune Clinical Study Site
-
-
North Carolina
-
Fayetteville, North Carolina, Forenede Stater, 28304
- Rekruttering
- Altimmune Clinical Study Site
-
-
Ohio
-
Brooklyn, Ohio, Forenede Stater, 44144
- Rekruttering
- Altimmune Clinical Study Site
-
Springboro, Ohio, Forenede Stater, 45066
- Rekruttering
- Altimmune Clinical Study Site
-
Westlake, Ohio, Forenede Stater, 44145
- Rekruttering
- Altimmune Clinical Study Site
-
-
Rhode Island
-
East Greenwich, Rhode Island, Forenede Stater, 02818
- Rekruttering
- Altimmune Clinical Study Site
-
-
Texas
-
Austin, Texas, Forenede Stater, 78757
- Rekruttering
- Altimmune Clinical Study Site
-
Bellaire, Texas, Forenede Stater, 77401
- Rekruttering
- Altimmune Clinical Study Site
-
Brownsville, Texas, Forenede Stater, 78520
- Rekruttering
- Altimmune Clinical Study Site
-
Corpus Christi, Texas, Forenede Stater, 78404
- Rekruttering
- Altimmune Clinical Study Site
-
Dallas, Texas, Forenede Stater, 75230
- Rekruttering
- Altimmune Clinical Study Site
-
Edinburg, Texas, Forenede Stater, 78539
- Rekruttering
- Altimmune Clinical Study Site
-
Farmers Branch, Texas, Forenede Stater, 75234
- Rekruttering
- Altimmune Clinical Study Site
-
Forney, Texas, Forenede Stater, 75126
- Rekruttering
- Altimmune Clinical Study Site
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- Altimmune Clinical Study Site
-
Georgetown, Texas, Forenede Stater, 78626
- Rekruttering
- Altimmune Clinical Study Site
-
Houston, Texas, Forenede Stater, 77004
- Rekruttering
- Altimmune Clinical Study Site
-
Houston, Texas, Forenede Stater, 77079
- Rekruttering
- Altimmune Clinical Study Site
-
Kingwood, Texas, Forenede Stater, 77339
- Rekruttering
- Altimmune Clinical Study Site
-
Pasadena, Texas, Forenede Stater, 77505
- Rekruttering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Forenede Stater, 78215
- Rekruttering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Forenede Stater, 78209
- Rekruttering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Altimmune Clinical Study Site
-
Sugar Land, Texas, Forenede Stater, 77479
- Rekruttering
- Altimmune Clinical Study Site
-
Waco, Texas, Forenede Stater, 76710
- Rekruttering
- Altimmune Clinical Study Site
-
-
Utah
-
Ogden, Utah, Forenede Stater, 84405
- Rekruttering
- Altimmune Clinical Study Site
-
West Jordan, Utah, Forenede Stater, 84088
- Rekruttering
- Altimmune Clinical Study Site
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Rekruttering
- Altimmune Clinical Study Site
-
-
-
-
Puerto Rico
-
San Juan, Puerto Rico, Puerto Rico, 00927
- Rekruttering
- Altimmune Clinical Study Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
All subjects:
- No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
- Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
- Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
- Subject agrees to have liver biopsy(ies) as required per protocol
Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening
Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing
Exclusion Criteria:
- Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
- Uncontrolled T2D or clinically significant persistent hyperglycemia
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Placebo SC Injection |
|
Eksperimentel: Pemvidutid 2,4 mg
|
Pemvidutide SC Injection |
|
Eksperimentel: Pemvidutide 1.8 mg
|
Pemvidutide SC Injection |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Outcome Event
Tidsramme: Baseline through end of study (approximately Month 60)
|
Time to first occurrence of any of the following events through the end of the study: Histologic progression to cirrhosis (F4) on liver biopsy; Liver related events; Liver transplantation; or Death due to any cause |
Baseline through end of study (approximately Month 60)
|
|
Histological Response: MASH resolution
Tidsramme: Baseline through Week 52
|
Proportion of subjects achieving MASH resolution (according to NASH Clinical Research Network [CRN] classification) without worsening of fibrosis |
Baseline through Week 52
|
|
Histological Response: Fibrosis improvement
Tidsramme: Baseline through Week 52
|
Proportion of subjects achieving ≥ 1 stage improvement in liver fibrosis according to the NASH CRN fibrosis staging system without worsening of MASH |
Baseline through Week 52
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH
Tidsramme: Baseline through Week 52
|
Baseline through Week 52
|
|
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis
Tidsramme: Baseline through Week 52
|
Baseline through Week 52
|
|
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- ALT-801-301
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .